Project Overview

A thorough understanding of how nanoparticles interact with tissues and cells in vivo is essential to accelerate the clinical translation process. Various tools will be applied to reveal the mechanisms of nanoparticle transport in vivo, allowing the development of new strategies for nanomaterial design.

Machine learning and artificial intelligence (AI) will also be applied to optimize nanotechnology-based drug delivery, “closing the loop” of nanoparticle synthesis, characterization, refinement, and testing or predicting activity in vitro and in vivo.

The incorporation of nanobiotechnology with molecular diagnostics (genomic/proteomic/celomic Nanosensors) can be deployed to improve the sensitivity, specificity, and accuracy of in vitro diagnostics. In our TRP,

We are developing various nanosensor platforms

• magnetic
• electrical
• optical
  

To discover and translate novel circulating biomarkers for different clinical applications

• metabolic diseases
• neurodegenerative diseases
• cancers
• infectious disease

Molecular imaging enables us to non-invasively visualise cellular functions and biological processes in living subjects, allowing accurate diagnosis of diseases at early stages. The novel properties of nanoparticles enable molecular imaging to have high resolution and sensitivity. Compared with small molecule-based contrast agents, nanoparticles exhibit excellent biodistribution, long circulation times, and other various functions.

Furthermore, multifunctional nanomaterials can serve as multimodal imaging agents or theranostic agents. Nevertheless, clinical translation of nanomaterials has been much slower than that of small molecule-based materials. Many clinical challenges, including toxicity, biocompatibility, targeting efficacy, and long-term stability of nanoparticles, will be addressed in this theme to promote their clinical translation.

Nanoparticles are the logical and encouraging tool for the delivery of medicine in a controlled and targeted manner. Nanotherapeutics are expected to provide targeted drug delivery, improve drug solubility, extend drug half-life, improve a drug’s therapeutic index, and reduce a drug’s immunogenicity, which has the potential to revolutionize the treatment of many diseases.

In this theme, various nanocarriers

• liposome
• nanocrystal
• virosome
• polymer therapeutics
• nanoemulsion
• inorganic nanoparticle

For different types of drugs, such as proteins/peptides, chemotherapeutics, RNA therapeutics

• siRNA
• mRNA

will be developed.

Immunomodulation, that is tuning how the immune system responds to exogenous and endogenous danger stimuli, represents a bubbling field of research in nanomedicine. The complexity under which the immune system operates, however, is staggering. An intricate network of cell types and subtypes direct the concerted actions of the innate and adaptive arms of the immune system. They coordinate, through different signaling molecules, the response against danger signals, and curb, in healthy conditions, the abnormal reaction against self-antigens that arise in autoimmune diseases.

The possibilities for nano-enabled immunomodulation are therefore multiple, and so are the challenges. We aim to

• Apply various nanotechnologies for effective targeting of dendritic cells (DCs) to induce immune tolerance
• Design nanomedicines to overcome various issues of adoptive T-cell therapy (ACT)
• Develop Nanovaccines against cancer and infectious diseases

In this theme, our TRP will tackle key issues related to the clinical development of nanomedicine, including biological challenges, large-scale manufacturing, biocompatibility and safety, government regulations, and the overall cost-effectiveness of nanomedicine.

It is the ultimate goal of this TRP to build up the expertise and capability in characterizing various newly developed nanoplatforms, conducting preclinical studies on the nano formulas for submission to regulatory agencies, scaling up laboratory preparation of nanomaterials according to regulatory and industry standards for early clinical trials, designing and conducting clinical trials of the de novo nanoplatforms.